Nektar Therapeutics
NKTR
$8.51
-$0.10-1.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 87.25M | 98.43M | 93.14M | 93.16M | 90.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.25M | 98.43M | 93.14M | 93.16M | 90.17M |
| Cost of Revenue | 22.15M | 30.69M | 29.99M | 37.99M | 35.24M |
| Gross Profit | 65.10M | 67.74M | 63.15M | 55.17M | 54.93M |
| SG&A Expenses | 80.95M | 76.75M | 76.94M | 79.13M | 76.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 227.08M | 228.35M | 229.03M | 228.26M | 222.83M |
| Operating Income | -139.83M | -129.92M | -135.90M | -135.10M | -132.66M |
| Income Before Tax | -133.19M | -119.20M | -168.31M | -177.16M | -176.01M |
| Income Tax Expenses | -152.00K | -239.00K | -9.00K | -79.00K | -172.00K |
| Earnings from Continuing Operations | -133.04 | -118.96 | -168.30 | -177.08 | -175.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -133.04M | -118.96M | -168.30M | -177.08M | -175.84M |
| EBIT | -139.83M | -129.92M | -135.90M | -135.10M | -132.66M |
| EBITDA | -136.62M | -125.53M | -130.19M | -128.69M | -125.54M |
| EPS Basic | -9.52 | -8.73 | -12.56 | -13.51 | -13.79 |
| Normalized Basic EPS | -7.09 | -6.57 | -6.81 | -6.86 | -6.81 |
| EPS Diluted | -9.53 | -8.74 | -12.56 | -13.51 | -13.79 |
| Normalized Diluted EPS | -7.07 | -6.54 | -6.81 | -6.86 | -6.81 |
| Average Basic Shares Outstanding | 55.92M | 54.84M | 53.59M | 52.33M | 51.06M |
| Average Diluted Shares Outstanding | 56.17M | 55.09M | 53.59M | 52.33M | 51.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |